The immunomodulatory effects of psychedelics in Alzheimer's disease-related dementia.
Neuroscience January 9, 2025 Alireza Mohammad Hosseini, Hossein Khaleghzadeh-Ahangar, Atena Rahimi
Alzheimer's disease accounts for 60% of dementia cases, and no cure exists. Recent research suggests psychedelics may reduce neuroinflammation by activating 5HT2A receptors, lowering proinflammatory cytokines such as TNF-α and IL-6. Additionally, psychedelics may promote neuroplasticity by increasing brain-derived neurotrophic factor (BDNF) levels through sigma-1 receptor stimulation. This review examines these potential effects on Alzheimer's disease from neuroinflammatory and neuroplasticity perspectives.